Objective. The objective of this literature review was to evaluate the existing evidence regarding the cost-effectiveness of treatment options in IBD. Methods. A systematic review of the literature was conducted to identify economic evaluations of IBD therapy. The literature search was performed using electronic databases MEDLINE and EMBASE. Searches were limited to full economic evaluations published in English or French between 2004 and 2016. Results. A total of 5,403 potentially relevant studies were identified. After screening titles and abstracts, 48 studies were included, according to the eligibility criteria. A total of 56% and 42% of the studies were assessing treatments of UC or CD, respectively. Treatment options under evaluation included biological agents, mesalamine, immunosuppressants, and surgery. The majority of studies evaluated the cost-effectiveness of biological treatments. Biological therapies were dominant in 23% of the analyses and were cost-effective according to a $CAD50,000/QALY and $CAD100,000/QALY threshold in 41% and 62% of the analyses, respectively. Conclusion. This literature review provided a comprehensive overview of the economic evaluations for the different treatment options for IBD over the past 12 years and represents a helpful reference for future economic evaluations.
Introduction
Inflammatory bowel diseases (IBD) are chronic, progressive, and disabling inflammatory conditions that affect the gastrointestinal (GI) track. Although not fatal, these conditions are associated with many symptoms, which have a major impact on patients' quality of life, including abdominal pain, fever, vomiting, diarrhea, rectal bleeding, anemia, and weight loss [1] [2] [3] . Patients with IBD often experience periods of remission alternating with periods of disease activity defined as relapse episodes [4, 5] .
IBD consist primarily of Crohn's disease (CD) and ulcerative colitis (UC), which are distinguished by the location and the nature of the inflammation. Specifically, CD occurs most commonly in the ileum and colon although it can affect any part of the digestive system. This condition is associated with deep and transmural mucosal inflammation and is characterized by segmental inflammation along the GI track. Patients diagnosed with CD often suffer from fistulas and perianal impairments. As opposed to CD, UC is mostly associated with continuous and diffused inflammation. Thus, the inflammation is often limited to the inner lining of the colon and rectum area; patients with UC generally present symptoms such as bloody diarrhea as well as mucus or pus in stools.
As opposed to several other chronic or inflammatory diseases, IBD affect a young population, as the first onset is generally seen in early adulthood or even in late adolescence [6] . Several risk factors have been attributed to the onset of IBD, including the environment and Western lifestyle, which is associated with smoking, a diet rich in fat and sugar, excessive consumption of drugs, and high socioeconomic status. Genetic factors play an important role in disease susceptibility, with over 200 genetic loci being associated with CD and UC. Moreover, environmental factors, such as the intestinal flora, play a central role in the initiation
Objective
As the economic burden of IBD is significant, numerous economic evaluations assessing the cost-effectiveness of treatment options in IBD have been performed during the past years. The objective of this literature review was to explore the existing evidence regarding the cost-effectiveness of these treatments.
Methods

Literature Search.
A systematic review of the literature was conducted to identify complete economic evaluations of IBD therapy. The review question was established using the PICO method [67] : population consisted of patients with IBD; interventions and comparators were standard therapies for IBD (drugs or surgery); outcomes of interest were results of cost-utility analyses (CUA), cost-effectiveness analyses (CEA), cost-minimization analyses (CMA), costconsequence analyses (CCA), or cost-benefit analyses (CBA). CUA were expressed in terms of cost per QALY whereas CEA were expressed in terms of cost per remission, cost per response, cost per life year gained (LYG), cost per mucosal healing (MH), or cost per days without symptoms or steroids (DWSS).
A structured literature search was performed using electronic databases MEDLINE and EMBASE, in addition to a manual search of health technology reports and NICE technology appraisals that were not published in a peerreviewed journal. PubMed was also searched to ensure that more recent studies (June 18th 2015 to June 18th 2016) not yet indexed in MEDLINE were identified. The keywords used for search were "crohn disease", "crohn's disease", "ulcerative colitis", "inflammatory bowel disease", and "IBD", combined with the National Health Service Economic Evaluation Database (NHS EED) filters for economic evaluations. The search was limited to studies that were published in English or French, between 2004 and 2016 (June 18th). Furthermore, a cross-reference search was performed to identify additional publications.
Study Selection.
Studies were initially selected based on titles and abstracts. Full-text articles of studies deemed eligible according to the abstract were then reviewed using a predefined eligibility form. Only full economic evaluations of IBD therapy available as full-text articles were included in this review. Studies were excluded if they were not full economic evaluations such as cost of illness, costs studies, or systematic review. All eligibility criteria were defined a priori. Study selection was performed by two independent reviewers for validation purposes. Disagreement between the reviewers was discussed and resolved by consensus.
Data Extraction.
For each economic evaluation selected for inclusion, the following characteristics and parameters were extracted using a self-developed data extraction form: first author, journal, year of publication, title, type of funding, country, type of evaluation, time horizon, perspective, population, treatments of interest, comparators, type of model, 
Results
Literature Search.
A flowchart describing the selection of studies included in this systematic review is presented in Figure 1 . A total of 5,403 potentially relevant studies were identified by the literature search. After the screening of titles and abstracts, 78 full-text articles were assessed according to the eligibility criteria. Of these studies, 48 articles meeting inclusion criteria were included.
Overview of Included Studies.
More than half of the included studies (56%) were assessing treatments of UC, 42% were evaluating treatments of CD, and only 1 study analyzed treatment for both CD and UC patients (Table 1) . Different treatment options were evaluated such as IFX, ADA, other biological treatments (golimumab, natalizumab, or VED), 5-ASA, immunosuppressants (AZA, 6MP, MTX, or cyclosporine), surgery (colectomy or Ileal Pouch-Anal Anastomosis (IPAA)), and granulocyte-monocyte aphaeresis (GMA). Overall, most studies were CUA that assessed the cost-effectiveness of a new biological therapy from a healthcare system perspective over a time horizon of 1 year or less. Moreover, nearly half of the studies used standard of care as a comparator. Furthermore, Canadian, American, and European studies accounted for 13%, 29%, and 52% of all the studies, respectively.
Modelling Approach and Health State Definition.
Half of the included studies used Markov modelling while one-third used decisions tree models. As for the remaining studies, some had no specific models employed [29, 30, 34, 65] or reported [33, 45] . The economic evaluations (EE) using a nonmodelling approach derived mainly from prospective data analysis or randomized clinical trials, whereas the studies not reporting their modelling approach were EE reports from the Canadian Agency of Drug Technology in Health (CADTH). Various criteria and scales, often based on previous clinical trials' remission and response definitions, defined models' health states. Among the studies assessing treatments for CD, a high proportion of the studies defined their health states according to Crohn's Disease Activity Index (CDAI), while some studies used the Harvey-Bradshaw Index (HBI). In economic evaluations assessing treatments for UC, most studies defined their health states according to the Mayo score, while others based their health states on symptom recurrence, on the Ulcerative Colitis Disease Activity Index (UCDAI) definition, on the Simple Clinical Colitis Activity Index (SCAI), or on the Physician Global Assessment (PGA).
Cost Parameters.
Several cost parameters were taken into account in the included studies. More specifically, all studies reported drug costs, including curative and supportive treatment costs. Moreover, costs associated with hospitalization and outpatient visits were comprised in 73% and 69% of the studies, respectively, while costs associated with surgical procedures were reported in 67% of the studies. Imaging, lab tests (tuberculin skin, hepatitis B blood tests, and biochemistry testing), and endoscopy costs were included in 42%, 38%, and 17% of the study, respectively. Among studies assessing the cost-effectiveness of a biological treatment, 70% included infusion costs.
Outcomes.
As most included studies were CUA, results were most frequently expressed in terms of cost per QALY.
As for the CEAs, results were reported in terms of cost per response or remission, cost per DWSS, cost per LYG, and cost per MH.
Cost-Effectiveness Results.
For comparison purposes, only CUA results for CD and UC were taken into account, which are presented in Tables 2 and 3 , respectively.
Cost-Effectiveness of Biological Therapies.
The majority of studies evaluated the cost-effectiveness of biological treatments. More specifically, regardless of the IBD type and the comparative treatment, biological therapies were dominant in 23% of the analyses and were cost-effective according to a $CAD50,000/QALY and $CAD100,000/QALY threshold in 41% and 62% of the analyses, respectively. Biological treatments tended to be more cost-effective when compared with surgery (dominant in 43% and cost-effective according to a $CAD50,000/QALY ratio in 57% of the analyses) and when compared with other biological treatments (dominant in 48% and cost-effective according to a $CAD50,000/QALY ratio in 52% of the analyses), rather than with standard of care (dominant in only 8% of the analyses and cost-effective in 33% of the analyses according to a $CAD50,000/QALY threshold). In CD, the incremental cost-effectiveness ratio (ICER) of biological treatments ranged from dominant to $CAD32,088,410/QALY when IFX or ADA maintenance treatment was compared to IFX or ADA induction treatment. Moreover, ADA tended to lead to more favourable ICERs than IFX when compared to standard of care, while IFX led to more favourable ICERs than ADA when compared to other biological treatments. Notably, moderate CD treatment regimens encountered greater cost-effectiveness ratios (CERs) compared to severe CD.
In the context of UC, dominance was mostly reported in studies where biological treatments were compared with other biological treatments or surgery. Moreover, all analyses were under a $CAD100,000/QALY threshold when IFX or ADA alone was compared with standard of care.
As for the Canadian setting, all studies in CD comparing biological treatments to standard (STD) of care resulted in an ICER above the $CAD100,000/QALY threshold. The opposite is seen in UC, where all studies resulted in an ICER under the $CAD100,000/QALY threshold. Furthermore, all ICERs resulting from the comparison of GOL to ADA were dominant.
Cost-Effectiveness of Immunosuppressants.
Most included studies assessing the cost-effectiveness of an immunosuppressant demonstrated that these treatments are cost-effective. More specifically, in the context of CD, AZA and cyclosporine were dominant alternatives when compared to therapy excluding immunosuppressants, when compared with MTX and when compared to standard of care. Moreover, cyclosporine was cost-effective according to a $CAD50,000/QALY threshold when compared with surgery.
In UC, only 1 economic evaluation was retrieved and indicated that immunosuppressant was a dominant alternative when compared to standard of care and was costeffective according to a $CAD50,000/QALY willingness to pay threshold when compared with surgery.
Cost-Effectiveness of Mesalamine (5-ASA).
All studies assessing the cost-effectiveness of 5-ASA were performed in the context of UC and compared 5-ASA with different 5-ASA formulations, doses, and treatment regimen. 5-ASA was dominant in 72.7% of the analysis and cost-effective according to a $CAD50,000/QALY willingness to pay (WTP) threshold in 81.9% of the analyses.
Cost-Effectiveness of Surgery.
Surgery was evaluated in treatments for UC only and was dominant when colectomy was compared with standard of care. However, when colectomy was performed at an early stage and combined with IPAA, surgery was not cost-effective according to a $CAD100,000/QALY WTP threshold compared to standard of care.
Discussion
Recent years have witnessed a rapid growth in IBD treatments. More specifically, the addition of biological treatments in the therapeutic arsenal of IBD has allowed significant clinical benefits, although it is associated with a substantial economic burden. Numerous economic evaluations have been performed in the last years in order to evaluate the costeffectiveness of IBD treatments. The objective of this literature review was to explore the existing evidence regarding the cost-effectiveness of IBD treatments. This review found that a high proportion of biological therapies were costeffective according to a $CAD100,000/QALY. Studies evaluating biological treatments in patients with severe disease and inadequate response to conventional therapies were found to be particularly cost-effective. Immunosuppressants and 5-ASA were also cost-effective strategies. On the other hand, the ranged ICER presented for IFX and ADA maintenance therapy versus induction therapy in CD was substantially wide. This variation could be explained by change in treatment regimen costs, despite the similarity between the associated QALY values. For the Canadian studies, the results seemed to differ by type of IBD, where ICERs for CD were much higher than ICERs for UC. Up to now, other literature reviews on economic evaluations of IBD treatments were performed. Most of these studies assessed the cost-effectiveness of biological treatments only [24, [69] [70] [71] [72] [73] [74] [75] [76] , while only a few have taken into consideration all treatments for IBD [77, 78] . The present study is considering all IBD treatment options, including biological agents (IFX, ADA, GOL, NAT, and VED), immunosuppressants (AZA, 6MP, and cyclosporine), 5-ASA, GMA, and surgery (colectomy, IPAA). The findings of the present study are in line with the results of the previous literature reviews.
This study provides an exhaustive and complete overview of the economic evaluations performed in the context of IBD during the past years. A rigorous systematic review was conducted according to a predefined protocol, based on best practice guidelines. Even if this was not a specific selection criterion, economic evaluations included in this review were, in general, of good quality. Moreover, a 12-year time period was covered, which allowed the identification and the selection of a large number of relevant costeffectiveness and cost-utility analyses. Such a long timeframe provided a good overview of the key characteristics of pharmacoeconomic analyses conducted in IBD during the last years. Furthermore, a high proportion of studies were of Canadian and American origin, which is in line with the high prevalence and incidence rates of IBD in theses' respective countries. Among other things, Canada detains one of the highest IBD prevalence and incidence worldwide.
However, this review has some limitations. This review was limited to English and French articles only. In addition, this review did not use a standardized tool for assessing the methodological quality of included studies. Another limitation involves the heterogeneity and variability of the characteristics and parameters of the studies included in this literature review. For instance, the methods used to assess the effectiveness differed from one study to the other. Many studies in UC or in CD used different disease progression index scores for definition of their model health states, including CDAI, HBI, or UCDAI scores. However, the latter scores are not based on the same patient disease characteristics and could therefore explain the variability in effectiveness among the studies. Moreover, different time horizons were chosen among included studies, which could have accounted for variability among studies. As IBD are chronic diseases, a longer time horizon allows better capturing remission and relapsing cycles and complications. However, a low proportion of studies have accounted for such a long time horizon. IBD complications, such as gastrointestinal cancers, are widely acknowledged as a long-term complication, likely as a result of chronic inflammation [79, 80] . Though, only few authors have incorporated colorectal cancer (CRC) risk in their economic model. In addition, the study population varied in terms of patients' age (adults or paediatric patients), previous exposition to treatment options (biological naïve patients, steroid refractory patients, and patients with inadequate response or medical contraindications for conventional therapies), and disease severity (patients with mild disease, patients with moderate to severe disease, patients with active luminal or fistulizing disease, and patients with acute exacerbations of disease).
Furthermore, the majority of selected economic evaluations have focused on a public healthcare system perspective, whereas only one study considered the societal perspective and led to a more favourable ICER than other studies comparing the same treatment options. IBD is a disease diagnosed as early adults, hence leading to a substantial impact on productivity loss and related costs. It has been demonstrated that biological therapies were associated with improved health outcomes, such as reduction in absenteeism [34, 81] . Considering that productivity losses account for a significant portion of the disease burden, the societal perspective is relevant and could have been considered [82] . Nevertheless, despite these limitations, this review adds to the current literature by providing a comprehensive overview of the existing economic evaluations in IBD therapy.
Conclusion
This literature review provided a comprehensive overview of the economic evaluations for the different treatment options for IBD over the past 12 years and represents a helpful reference for future economic evaluations.
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